Welcome to our dedicated page for Entero Therapeutics news (Ticker: ENTO), a resource for investors and traders seeking the latest updates and insights on Entero Therapeutics stock.
Entero Therapeutics, Inc. (Symbol: ENTO) is a late clinical-stage biopharmaceutical company dedicated to the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company focuses on addressing significant unmet needs in GI health through a robust pipeline of innovative programs.
Entero Therapeutics' key programs include:
- Latiglutenase: A Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic designed for the treatment of celiac disease. This program aims to improve the quality of life for patients by reducing gluten-induced symptoms.
- Capeserod: A selective 5-HT4 receptor partial agonist being developed for conditions such as gastroparesis. This program targets improving gastric motility and alleviating symptoms associated with delayed gastric emptying.
- Adrulipase: A recombinant lipase enzyme intended for patients with exocrine pancreatic insufficiency due to cystic fibrosis or chronic pancreatitis. This therapy is designed to support the digestion of fats and other essential nutrients.
Recently, Entero Therapeutics has highlighted new research through presentations that showcased the VCIEL scale, a novel tool for measuring small intestinal mucosal health. These presentations also provided insights from the comprehensive Phase 2 clinical trials of latiglutenase, demonstrating the company's commitment to advancing GI health research.
Located in Boca Raton, FL, Entero Therapeutics continues to forge strategic partnerships and collaborations to enhance its research and development efforts. With a dedicated team and a strong focus on innovation, the company is well-positioned to bring transformative therapies to market, addressing the critical needs of patients with GI diseases.
For more information, please contact Entero Therapeutics, Inc. at 777 Yamato Road, Suite 502, Boca Raton, FL 33431, phone: (561) 589-7020, or via email at info@enterothera.com. Media inquiries can be directed to Russo Partners, David Schull at (347) 956-7697 or david.schull@russopartnersllc.com and Liz Phillips at elizabeth.phillips@russopartnersllc.com.
Entero Therapeutics (NASDAQ: ENTO), a clinical-stage biopharmaceutical company focused on gastrointestinal (GI) diseases, has received a notification from Nasdaq regarding its delayed Form 10-Q filing. The company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the late submission of its quarterly report for the period ended June 30, 2024.
Entero Therapeutics has until October 21, 2024, to submit a compliance plan to Nasdaq. If approved, the company may receive an extension until February 17, 2025, to regain compliance. The delay is attributed to the resignation of Forvis Mazars, LLP as the company's independent auditors on August 9, 2024. Entero Therapeutics is currently seeking a new accounting firm and aims to file the Form 10-Q before the October deadline.
Entero Therapeutics (NASDAQ: ENTO) has provided a business update focusing on its lead product candidate, latiglutenase, for celiac disease treatment. The company plans to advance latiglutenase into a pivotal Phase 3 trial in 2025. Key developments include:
1. Submitting two Type D meeting requests to the FDA to optimize the Phase 3 trial design.
2. Proposing to reduce cohorts from three to two (1200 mg and placebo) to maximize efficacy and potentially reduce costs and trial duration.
3. Preparing to finalize histology-related secondary efficacy endpoints.
4. Streamlining the trial design to focus on severe and symptomatic patients with intestinal damage.
5. Completing a small financing of $1.9 million in gross proceeds.
6. Consolidating operations to the Boca Raton headquarters to reduce costs and improve efficiency.
Entero Therapeutics has announced agreements with holders of its existing warrants, allowing them to exercise their warrants at a reduced price of $1.09 per share. This exercise is expected to yield approximately $1.9 million in gross proceeds. In return, these holders will receive new warrants to purchase additional shares at the same price, exercisable for five years after stockholder approval. The transaction, conducted as an at-market deal under Nasdaq rules, involves issuing new warrants for up to 3,525,348 shares. Roth Capital Partners served as the financial advisor for this transaction.
Entero Therapeutics announced that their abstract on Celiac Disease research has been accepted for oral presentation at the 20th International Celiac Disease Symposium (ICDS) in Sheffield, UK, from September 5-7, 2024. The presentation will introduce a new VCIEL scale, aimed at assessing small intestinal mucosal health in Celiac Disease patients. Jack Syage, Ph.D., the President and Chief Scientific Officer, remarked that this advancement could significantly improve the precision of monitoring and diagnosing Celiac Disease, potentially enhancing treatment effectiveness.
The ICDS event details include the presentation titled 'A Composite Mucosal Scale for Celiac Disease Encompassing Both Morphology and Inflammation'. The symposium will be held at Sheffield City Hall, and registration is available through the ICDS website.
Entero Therapeutics has announced the publication of a novel algorithm for measuring intestinal damage in celiac disease. The VCIEL scale, detailed in Clinical Gastroenterology and Hepatology, combines architectural changes and inflammation metrics to provide a more sensitive and quantitative measure of small intestinal health. This innovation promises to improve the accuracy of histological evaluations and efficacy assessments of treatments for celiac disease. The significance of VCIEL was emphasized in a special editorial, underlining its potential impact on celiac disease research and clinical trials.
Entero Therapeutics, a biopharmaceutical company specializing in gastrointestinal (GI) disease therapies, will provide a corporate update at the 2024 BIO International Convention, held from June 3-6 in San Diego, CA. The company will present on June 4 at 10:30 a.m. PDT in Presentation Theater 4. The focus will be on their Phase 3 treatment for celiac disease. Interested parties can schedule meetings via the BIO One-on-One Partnering platform.
Entero Therapeutics presented two posters highlighting celiac disease research at the 2024 Digestive Disease Week Conference. The first presentation introduced the VCIEL scale, a new quantitative measure combining the villus height to crypt depth ratio (Vh:Cd) and intraepithelial lymphocyte density (IEL), showing improved sensitivity and accuracy in diagnosing small intestinal mucosal health. The second presentation focused on gluten intake thresholds needed to trigger positive serological responses, revealing higher levels than previously thought. These findings aim to enhance diagnostics and inform Phase 3 clinical trials for latiglutenase, their investigational celiac disease treatment.
FAQ
What is the current stock price of Entero Therapeutics (ENTO)?
What is the market cap of Entero Therapeutics (ENTO)?
What is Entero Therapeutics, Inc.?
What are the key programs of Entero Therapeutics?
What is latiglutenase?
What is capeserod?
What is adrulipase?
Where is Entero Therapeutics located?
How can I contact Entero Therapeutics?
Who are the media contacts for Entero Therapeutics?
What recent achievements has Entero Therapeutics made?